JP2006501207A5 - - Google Patents

Download PDF

Info

Publication number
JP2006501207A5
JP2006501207A5 JP2004525343A JP2004525343A JP2006501207A5 JP 2006501207 A5 JP2006501207 A5 JP 2006501207A5 JP 2004525343 A JP2004525343 A JP 2004525343A JP 2004525343 A JP2004525343 A JP 2004525343A JP 2006501207 A5 JP2006501207 A5 JP 2006501207A5
Authority
JP
Japan
Prior art keywords
formula
compound
crystalline form
composition
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004525343A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006501207A (ja
Filing date
Publication date
Priority claimed from GBGB0217504.0A external-priority patent/GB0217504D0/en
Application filed filed Critical
Publication of JP2006501207A publication Critical patent/JP2006501207A/ja
Publication of JP2006501207A5 publication Critical patent/JP2006501207A5/ja
Pending legal-status Critical Current

Links

JP2004525343A 2002-07-29 2003-07-28 有機化合物 Pending JP2006501207A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0217504.0A GB0217504D0 (en) 2002-07-29 2002-07-29 Organic compounds
GB0217504.0 2002-07-29
PCT/EP2003/008314 WO2004013156A1 (en) 2002-07-29 2003-07-28 Polymorphis of a known thiophenecarboxylic acid dodecahydrocyclopenta (a) phenanthrenyl ester

Publications (2)

Publication Number Publication Date
JP2006501207A JP2006501207A (ja) 2006-01-12
JP2006501207A5 true JP2006501207A5 (https=) 2009-05-07

Family

ID=9941275

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004525343A Pending JP2006501207A (ja) 2002-07-29 2003-07-28 有機化合物

Country Status (30)

Country Link
US (1) US7683048B2 (https=)
EP (2) EP1554303B1 (https=)
JP (1) JP2006501207A (https=)
KR (1) KR100688371B1 (https=)
CN (1) CN1305892C (https=)
AR (1) AR040692A1 (https=)
AT (1) ATE349459T1 (https=)
AU (1) AU2003251651B2 (https=)
BR (1) BR0313044A (https=)
CA (1) CA2493330C (https=)
CY (1) CY1106406T1 (https=)
DE (1) DE60310747T2 (https=)
DK (1) DK1554303T3 (https=)
EC (1) ECSP055579A (https=)
ES (1) ES2279970T3 (https=)
GB (1) GB0217504D0 (https=)
HK (1) HK1080484B (https=)
IL (2) IL166287A0 (https=)
MX (1) MXPA05001173A (https=)
MY (1) MY136407A (https=)
NO (1) NO20050806L (https=)
NZ (2) NZ537868A (https=)
PE (1) PE20040722A1 (https=)
PL (1) PL209409B1 (https=)
PT (1) PT1554303E (https=)
RU (2) RU2330043C2 (https=)
SI (1) SI1554303T1 (https=)
TW (1) TWI309164B (https=)
WO (1) WO2004013156A1 (https=)
ZA (1) ZA200500370B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
SI1775305T1 (sl) 2000-08-05 2015-01-30 Glaxo Group Limited S-fluorometil ester 6alfa,9alfa-difluoro-17alfa-((2-furanilkarboksil)oksi)- 11beta-hidroksi-16alfa-metil-3-okso-androst-1,4-dien-17-karbotiojske kisline kot protivnetno sredstvo
KR100831534B1 (ko) 2001-04-30 2008-05-22 글락소 그룹 리미티드 17.알파 위치에 시클릭 에스테르기를 지닌 항염증성의안드로스탄의 17.베타.-카르보티오에이트 에스테르 유도체
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0523656D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523654D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0603783D0 (en) * 2006-02-24 2006-04-05 Novartis Ag Organic compounds
RU2487131C2 (ru) * 2008-03-14 2013-07-10 Оцука Фармасьютикал Ко., Лтд. Ингибитор ммр-2 и/или ммр-9

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU550939A1 (ru) * 1975-05-19 1994-07-15 Институт химии древесины АН ЛатвССР 1,2,3,4,4а,4в,5,6,10,10а -декагидро -6- хлорацетоксиметил -1,4а-диметил -7- (1-метилэтил) -1- фенантренкарбоновая кислота или ее соли
JPH08291073A (ja) * 1995-04-22 1996-11-05 Kissei Pharmaceut Co Ltd 医薬品組成物及びその製造方法
GB0015876D0 (en) * 2000-06-28 2000-08-23 Novartis Ag Organic compounds

Similar Documents

Publication Publication Date Title
JP5466006B2 (ja) 非常に速い皮膚浸透率を有するアセトアミノフェン及び関連化合物の正荷電水溶性プロドラッグ
TWI692465B (zh) 酚系trpv1促效劑之前藥
CN104854105A (zh) 具有毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂活性的化合物
JP2002517438A (ja) 咳の治療のための組成物及び方法
CN102725261A (zh) 花生四烯酸类似物及用其进行镇痛治疗的方法
US20150238456A1 (en) Methods and compositions for administration of oxybutynin
EP3558380A1 (de) Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen
JP2006501207A5 (https=)
JP2009541455A5 (https=)
US6538035B2 (en) Use of tolterodine to treat asthma
JP2005531612A (ja) ネフォパムの製剤および痛みの治療におけるその使用
CN103833713A (zh) 硝克柳胺化合物晶iii型、其制法和其药物组合物与用途
JP2022508217A (ja) Task-1およびtask-3チャンネル阻害剤を含有する医薬投薬形態の製造方法、ならびに呼吸障害治療におけるその使用
TW202019887A (zh) 酚系trpv1促效劑之聚乙二醇化前藥
JP2006506402A (ja) 四級アンモニウム化合物およびその抗ムスカリン薬としての使用
AU2013368298B2 (en) Methods and compositions for administration of oxybutynin
CN106163505B (zh) 可吸入颗粒相关改进
CN101663036B (zh) 4-环丙基甲氧基-n-(3,5-二氯代-1-氧代-4-吡啶-4-基)-5-(甲氧基)吡啶-2-甲酰胺用于治疗颅脑创伤的用途
CN102665705A (zh) 包含非甾体抗炎药和秋水仙碱苷衍生物的活性成分的新组合
HK40093030A (zh) 含有格隆铵·水杨酸盐的药物
EP3338764A1 (de) Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen
RU2021119540A (ru) Глутарат 3-(1,2,3,6-тетрагидропиридин-2-ил)пиридина или его фармацевтически приемлемый сольват
JPH11209302A (ja) 抗掻痒剤
EP3338803A1 (de) Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen
WO2010145800A1 (en) Salts of tramadol and diflunisal and their crystal form in the treatment of pain